What are the recommended dosing, monitoring, and reversal guidelines for unfractionated heparin (UFH) and low‑molecular‑weight heparin (LMWH) in adult patients, including considerations for renal impairment and heparin‑induced thrombocytopenia (HIT)?

Heparin Guidelines: Dosing, Monitoring, and Management

Unfractionated Heparin (UFH)

Dosing Regimens

For VTE treatment, initiate UFH with an 80 U/kg IV bolus followed by 18 U/kg/hour continuous infusion 1, 2. This weight-based approach is critical because the predominant variable affecting heparin response is body weight 1.

For subcutaneous administration in VTE treatment, use 333 U/kg initial dose followed by 250 U/kg twice daily 2. This unmonitored subcutaneous regimen has demonstrated comparable efficacy to LMWH 3.

For VTE prophylaxis, administer 5000 units subcutaneously every 8 hours 3. While twice-daily dosing is sometimes used, three-times-daily administration is more effective in surgical patients, though it carries higher bleeding risk in medical patients 3.

Monitoring

Target aPTT ratio of 1.5-2.5 times control (approximately 50-70 seconds), which corresponds to anti-factor Xa levels of 0.3-0.7 IU/mL 1, 2, 4. The aPTT therapeutic range must be validated at your institution because reagent variability significantly affects results 4.

In patients with apparent heparin resistance (elevated acute phase reactants, high factor VIII levels), anti-factor Xa monitoring is superior to aPTT 5, 4. This is particularly relevant in COVID-19 and other inflammatory states where heparin resistance commonly occurs 5.

Monitor hemoglobin, hematocrit, and platelet count every 2-3 days through day 14, then every 2 weeks thereafter 3.

Platelet Monitoring for HIT

For patients with >1% HIT risk (most UFH recipients), monitor platelet counts every 2-3 days from day 4 to day 14 or until heparin is stopped 6. High-risk scenarios include:

• Curative UFH doses (medical or surgical contexts)
• Cardiac surgery with cardiopulmonary bypass
• Orthopedic surgery
• ECMO support 7

For patients with <1% HIT risk, platelet monitoring is not required 6.

Low-Molecular-Weight Heparin (LMWH)

Dosing Regimens

LMWH is preferred over UFH for most indications due to superior efficacy, safety, and convenience 8, 2, 6.

For VTE treatment:

• Enoxaparin: 1 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily 2
• Dalteparin: 200 units/kg subcutaneously once daily 2

For VTE prophylaxis:

• Enoxaparin 40 mg subcutaneously daily
• Dalteparin 5000 units subcutaneously daily 3

Once-daily dosing is preferred to reduce healthcare worker exposure and improve adherence 9.

Renal Impairment Considerations

With creatinine clearance <30 mL/min, UFH is preferred over LMWH 3, 2, 10, 4. LMWH undergoes renal clearance and accumulates in severe renal dysfunction, increasing bleeding risk.

If LMWH must be used in severe renal impairment:

• Reduce enoxaparin dose to 1 mg/kg once daily 1
• Consider dalteparin or tinzaparin, which have less renal metabolism 8, 10
• Monitor anti-factor Xa levels (target 0.5-1.0 IU/mL for twice-daily dosing, 1.0-2.0 IU/mL for once-daily dosing) 11, 10, 4
• Measure peak levels 4 hours after subcutaneous injection 10

Do not use LMWH in severe renal impairment if anti-factor Xa monitoring is unavailable 10.

For moderate renal impairment (creatinine clearance 30-50 mL/min), use standard LMWH doses with caution and consider anti-factor Xa monitoring 3.

Obesity Considerations

For patients >150 kg, use actual body weight for LMWH dosing but consider anti-factor Xa monitoring 11, 4. The therapeutic range depends on dosing interval as noted above.

Do not routinely monitor anti-factor Xa levels in obese patients; instead, use weight-based dosing 11. Only monitor if there are concerns about efficacy or bleeding.

Platelet Monitoring for HIT

Platelet monitoring is not routinely required for LMWH in most patients 2, 6. The HIT risk with LMWH is approximately 10 times lower than UFH 7.

Monitor platelets every 2-3 days from day 4 to day 14 in intermediate-risk scenarios:

• Surgical patients receiving prophylactic LMWH
• Cancer patients on therapeutic LMWH
• Cardiovascular surgery patients receiving postoperative LMWH 7

Do not monitor platelets in:

• Medical patients on prophylactic LMWH
• Obstetric patients
• Patients receiving LMWH for >30 days 7

Heparin-Induced Thrombocytopenia (HIT) Management

Diagnosis

Use the 4T score to assess pre-test probability:

• Low (4T ≤3): Exclude HIT, continue heparin 7
• Intermediate (4T 4-5) or High (4T ≥6): Stop all heparin immediately, order anti-PF4 antibodies, start alternative anticoagulation 7

Do not wait for laboratory confirmation if clinical probability is high 7.

Alternative Anticoagulants

First-line agents for HIT:

For normal renal function (CrCl >30 mL/min):

• Argatroban, bivalirudin, or danaparoid 7, 6
• Fondaparinux (off-label but increasingly used) 7

For severe renal impairment (CrCl <30 mL/min):

• Argatroban is the preferred agent 7, 6
• Initial dose: 1 mcg/kg/min (reduce to 0.5 mcg/kg/min in ICU patients, cardiac surgery, or Child-Pugh B hepatic impairment) 7
• Monitor with aPTT daily, targeting 2-3 times control, or preferably diluted thrombin time (target 0.5-1.5 mg/mL) 7

Argatroban is contraindicated in severe hepatic failure (Child-Pugh C) 7. In this setting, use bivalirudin, danaparoid, or fondaparinux 7.

Danaparoid is not recommended as first-line in severe renal failure 7. Use curative IV doses (not prophylactic doses) with anti-Xa monitoring using danaparoid-specific calibration 7.

Transition to Warfarin

Do not start warfarin until platelet count has recovered 3. Overlap with alternative anticoagulant for at least 5 days and until INR ≥2.0 3, 6. Warfarin alone in acute HIT can cause venous limb gangrene.

Cardiac Surgery with HIT

For urgent cardiac surgery in acute or subacute HIT, use bivalirudin over other alternatives 6.

Reversal of Anticoagulation

Protamine sulfate reverses UFH completely 4, 12. For LMWH, protamine provides only partial reversal (approximately 60% of anti-factor Xa activity) 4, 12.

Protamine dosing for UFH: 1 mg protamine per 100 units of heparin received in the last 2-3 hours.

Key Clinical Pitfalls

Avoid these common errors:

1. Using aPTT monitoring without institutional validation of the therapeutic range 4
2. Administering LMWH in severe renal impairment without dose adjustment or anti-factor Xa monitoring 10, 4
3. Starting warfarin before platelet recovery in HIT 3, 6
4. Continuing heparin when 4T score is intermediate or high while awaiting antibody results 7
5. Using prophylactic doses of alternative anticoagulants for HIT treatment (use therapeutic doses) 7
6. Administering platelet transfusions in suspected HIT, which can worsen thrombosis 13, 14
7. Failing to monitor for lupus anticoagulant in COVID-19 patients, which can falsely elevate aPTT 5